NCT05563766View on ClinicalTrials.gov

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

April 30, 2029

Study Completion Date

June 15, 2029

Conditions
Esophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastroesophageal Junction Carcinoma
Interventions
DRUG

Itraconazole

Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation

Trial Locations (7)

94304-1207

RECRUITING

VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto

48105-2303

NOT_YET_RECRUITING

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

27705-3875

RECRUITING

Durham VA Medical Center, Durham, NC, Durham

97207-2964

RECRUITING

VA Portland Health Care System, Portland, OR, Portland

75216-7167

RECRUITING

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas

77030-4211

RECRUITING

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

98108-1532

RECRUITING

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

All Listed Sponsors
collaborator

Durham VA Health Care System

FED

collaborator

VA Palo Alto Health Care System

FED

collaborator

Portland VA Medical Center

FED

collaborator

VA Puget Sound Health Care System

FED

collaborator

Michael E. DeBakey VA Medical Center

FED

collaborator

VA Boston Healthcare System

FED

collaborator

North Texas Veterans Healthcare System

FED

collaborator

VA Ann Arbor Healthcare System

FED

lead

VA Office of Research and Development

FED